Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population

Rozette, Nicole A.; Hellauer, Christina M; McKee, Chephra; Vazifedan, Turaj; Gabriel, Christos A.; Dice, James E.; Yokois, Nancy

doi:10.1093/ibd/izy093

Cited by 6 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, including 297 patients and 8381 IFX infusions, accelerated IFX infusions did not increase the risk of acute IR. This finding supports previous pediatric studies, suggesting that accelerated 1-h IFX infusions are safe (17–20,27,28). A shortened infusion duration of 30 minutes to 1 hour has been studied more extensively in adults with IBD (13–16,29–31).…”

Section: Discussionsupporting

confidence: 92%

“…To our knowledge, this is the largest study so far assessing the safety of accelerated versus standard IFX infusions in children with IBD. Previous studies consisted of smaller cohorts (16-116 children with IBD) (18)(19)(20)27,28) or lacked a control group (17). In addition, multiple studies (19,20) only included children who switched from standard to accelerated infusion, thus acting as their own controls.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study

Jagt

Galestin

Claesen

et al. 2023

Journal of Pediatric Gastroenterology &Amp; Nutrition

View full text Add to dashboard Cite

Objectives: Accelerated infliximab (IFX) infusions have shown to be safe in adults with inflammatory bowel disease (IBD), but data on its safety in pediatric IBD is limited. This study aimed to assess the incidence and timing of infusion reactions (IR) in children with IBD who received accelerated (1-h) versus standard (2-h) IFX infusions. Methods: This retrospective cohort study included IBD patients 4–18 years of age and initiated IFX between January 2006 and November 2021 at Amsterdam University Medical Centre, location Academic Medical Centre (AMC) and VU Medical Centre (VUmc). The AMC protocol was adjusted in July 2019 from standard to accelerated infusions with 1-h intrahospital post-infusion observation period, whereas in VUmc only standard infusions were administered without an observation period. After merging the departments in 2022, all VUmc patients were allocated to the accelerated infusions (AMC) protocol. Primary outcome was the incidence of acute IR among maintenance accelerated versus standard infusions. Results: Totally, 297 (150 VUmc, 147 AMC) patients (221 Crohn disease; 65 ulcerative colitis; 11 IBD-unclassified) with cumulative n = 8381 IFX infusions were included. No statistically significant difference in the per-infusion incidence of IR was observed between maintenance standard infusions (26/4383, 0.6% of infusions) and accelerated infusions (9/3117, 0.3%) (P = 0.33). Twenty-six of 35 IR (74%) occurred during the infusion, while 9 occurred post-infusion (26%). Only 3 of 9 IR developed in the intrahospital observation period following the switch to accelerated infusions. All post-infusion IR were mild, requiring no intervention or only oral medication. Conclusions: Accelerated IFX infusion without a post-infusion observation period for children with IBD seems a safe approach.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study

Jagt

Galestin

Claesen

et al. 2023

Journal of Pediatric Gastroenterology &Amp; Nutrition

View full text Add to dashboard Cite

show abstract

“…Reasons for exclusion were different patient populations (eg, no children or age unspecified) (n ¼ 48), no original research (n ¼ 5), different study design (not about rapid infusions or IR) (n ¼ 3) and no full texts (eg, conference abstracts or letter to the editor) (n ¼ 10). One study included patients ages 2 to 28 years old and 1 included patients ages 6 to 21 years old, but despite efforts to contact the authors, the data on children only could not be retrieved (7,8). These studies were, therefore, not included.…”

Section: Included Studiesmentioning

confidence: 99%

Safety of Rapid Infliximab Infusions in Children

Wassenaer

Oosterhout

Daams

et al. 2020

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Objectives: The aim of the study was to assess whether the incidence of infusion reactions (IR) increases after rapid (≤1 hour) infliximab (IFX) infusions, compared with standard (2–3 hour) infusions in children. Methods: Systematic review including studies describing the number of IR after rapid IFX infusion in children ages 0 to 18 years. Results: Four records were included (3 retrospective, n = 498, 347 standard infusions, 3703 rapid infusions). Reported incidences of IR ranged from 0% to 2% of infusions in standard groups (reported 95% confidence intervals [CIs] ranged from 0% to 7%) and from 0% to 2% of infusions in rapid groups (reported 95% CIs ranged from 0% to 12%). None of the studies included reported a significant difference in incidence of IR between the 2 groups. Conclusions: There is insufficient evidence to conclude whether the rate of IR after rapid IFX increases. The consistent finding of no increase in IR in all studies and the low rate of observed IR suggests there is no significant difference in rate of IR.

show abstract

Infliximab

2018

Reactions Weekly

View full text Add to dashboard Cite

Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population

Cited by 6 publications

References 46 publications

Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study

Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study

Safety of Rapid Infliximab Infusions in Children

Infliximab

Contact Info

Product

Resources

About